LAS VEGAS — Despite some recent setbacks, including ones in the RNAi field, oligonucleotide therapeutics are still likely to become the third major drug-development platform alongside small molecules and biologics in a matter of a few years, according to Art Krieg, the former CSO
Following a positive recommendation from the EMA committee, the European Commission is expected to issue a decision in September regarding marketing Tarceva as a first-line treatment for EGFR-mutation-positive NSCLC.
Roche Licenses Rights to Develop Assay, Companion Dx for EGFR Mutations
In separate agreements, Roche has obtained a worldwide sub-license from Genzyme to develop the EGFR assay, and will collaborate with OSI Pharmaceuticals to develop the companion diagnostic.
AVEO to Identify Patient-Selection Biomarkers for OSI in $20M Cash and Equity Deal
OSI will have access to AVEO's tumor models, archives, and biomarkers and will also acquire non-exclusive access to AVEO's proprietary bioinformatics platform.
After Mulling NC, Pennsylvania, OSI Opts to Abandon Long Island HQ, Consolidate in Suburban NY
OSI officials this week said that the availability of a long-vacant biocampus, the presence of a nearby budding biocluster, the promise of tax breaks and other economic incentives — and discontent with leaders in its current home base in New York's Long Island region — persuaded it to bypass North Carolina and Pennsylvania in favor of the Westchester County site.